CASE REPORT

Case Report: Expanding the tumour spectrum associated with the Birt-Hogg-Dubé cancer susceptibility syndrome [version 1; peer review: 2 approved]

Patrick R. Benusiglio¹,²*, Sophie Gad³*, Christophe Massard², Edith Carton², Elisabeth Longchampt⁴, Tiffany Faudot³, Jérôme Lamoril⁵, Sophie Ferlicot¹,⁶

¹Centre Expert National Cancers Rares PREDIR, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, 94275, France
²Département de Médecine Oncologique, Gustave Roussy Cancer Campus, Villejuif, 94805, France
³Laboratoire de Génétique Oncologique EPHE, INSERM U753, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre et Gustave Roussy Cancer Campus, Villejuif, 94276, France
⁴Service d'Anatomie Pathologique, Hôpital Foch, Suresnes, 92151, France
⁵Département de Génétique Moléculaire, Hôpital Bichat – Claude Bernard, AP-HP, Paris, 75018, France
⁶Service d'Anatomie Pathologique, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, 94275, France

* Equal contributors

Abstract

Patients with the Birt-Hogg-Dubé cancer susceptibility syndrome are at high risk of developing renal cell carcinoma, pulmonary cysts and pneumothorax, and skin lesions called fibrofolliculomas. Here we report the case of a Birt-Hogg-Dubé patient with a primary clear cell carcinoma of the thyroid (a very rare type of thyroid cancer), and FLCN loss of heterozygosity within the tumour, providing molecular evidence for this association. Our findings expand the tumour spectrum associated with this syndrome. It is paramount to identify individuals with Birt-Hogg-Dubé so that they, and subsequently their affected relatives, can benefit from tailored cancer screening and prevention.

Keywords

Birt-Hogg-Dubé, clear cell carcinoma, fibrofolliculoma, hereditary cancer, pneumothorax, thyroid carcinoma.
Corresponding author: Patrick R. Benusiglio (pbenusiglio.wk@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: Financial support to the PREDIR Centre (PRB, SF) and the INSERM U753 Research Unit (SG) is provided continuously by the Ligue Nationale contre le Cancer (Comités de l'Indre et du Cher), the Myrovlytis Trust (BHD Foundation) and the Fondation Gustave Roussy.

Copyright: © 2014 Benusiglio PR et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

How to cite this article: Benusiglio PR, Gad S, Massard C et al. Case Report: Expanding the tumour spectrum associated with the Birt-Hogg-Dubé cancer susceptibility syndrome [version 1; peer review: 2 approved] F1000Research 2014, 3:159 (https://doi.org/10.12688/f1000research.4205.1)

Birt-Hogg-Dubé (BHD) is a cancer susceptibility syndrome caused by dominantly-inherited mutations in the folliculin gene \textit{FLCN}. Affected individuals are at risk of renal cell carcinoma (RCC), spontaneous pneumothorax associated with lung cysts and white skin papules called fibrofolliculomas. RCC affects 34\% of mutation carriers, and most tumours are of chromophobe, oncocytoma, hybrid or clear cell histology. Thirty-eight and 84\% of BHD cases have a history of pneumothorax and fibrofolliculomas, respectively. We report the case of a BHD patient with a primary clear cell carcinoma of the thyroid and provide molecular evidence supporting an association between the BHD syndrome and this rare tumour.

\textbf{Case report}

A 72 year-old French Caucasian male with a history of hypertension and early-stage rectal carcinoma (diagnosed at the age of 64) complained of a right thyroid nodule. Thyroid function tests were normal. Medication at the time consisted of irbesartan, lercanidine and aspirin. The nodule was suspect on echography, and an operation was scheduled. Intraoperative fresh frozen analysis confirmed the malignant nature of the lesion, and thyroidectomy with paratracheal lymph node dissection was performed. The pathologist described a poorly circumscribed tumour measuring approximately 3.5 × 2 cm. On microscopic examination, nests of carcinomatous elements separated by a fibrous vascularized stroma were observed (Figure 1, hematoxylin and eosin). The neoplastic cells had a small, peripheral nucleus, with abundant clear cytoplasm. There was limited invasion of the capillaries, but widespread infiltration of the surrounding normal thyroid parenchyma and of the surgical margins. Staining was positive for cytokeratin 7 (Dako OV-TL 12/30), and negative for cytokeratin 20 (Dako Ks 20.8) and thyroglobulin (Dako DAK-Tg6). Lymph nodes were free of tumours. Histological examination was suggestive of a clear cell RCC metastatic to the thyroid, but no primary lesion was seen on 18-F fluorodeoxyglucose (FDG) positron emission tomography/computerised tomography (PET/CT) scans, in the kidneys or elsewhere. It was therefore concluded that the patient had a primary clear cell carcinoma of the thyroid. In the absence of papillary structures, significant nuclear grooves or pseudo-inclusions, the tumour was considered a variant form of follicular carcinoma. Adjuvant radiotherapy was administered (46 Gy over five weeks). Two years later, multiple bilateral pulmonary nodules were seen on follow-up PET/CT scan. Two were surgically resected, and their microscopic appearance matched what had been observed in the thyroid two years earlier, except that complementary analyses now showed positive nuclear staining for Thyroid Transcription Factor 1 (TTF-1) (Figure 2), confirming as a result that the organ primarily affected was indeed the thyroid. There were no metastases in other organs, and the kidneys, as seen previously, were free of tumour.

The patient also had multiple pulmonary air-filled cysts on baseline and follow up PET/CTs, as well as a right recurring pneumothorax. Family history was relevant as his son and two nephews had a history of spontaneous pneumothorax. On dermatological examination, one could see face fibrofolliculomas. Both these pulmonary and dermatological features were highly suggestive of BHD, and a blood sample was sent for \textit{FLCN} analysis. Sequencing of the exons and of their flanking regions was performed with the Big Dye Terminator v.1.1 kit on the ABI 3730 sequencer (Applied Biosystems), and a search for large deletions was done using Multiplex Ligation-dependent Probe Amplification (MLPA, MRC-Holland). The c.1062G>C mutation in exon 9, which is classified as pathogenic by the SIFT (http://sift.jcvi.org/), Polyphen (http://genetics.bwh.harvard.edu/pph2/) and SNPs3D (http://www.snps3d.org/) bioinformatics prediction tools, was identified. It likely interferes with intron 10 splicing as it is located on the last base of exon 9,

To investigate the association between BHD and the thyroid carcinoma, we performed FLCN analysis on tumoral and adjacent normal tissues. DNA was extracted from frozen sections with the QIAamp DNA mini kit (Qiagen), and exons and exon-intron junctions were sequenced with the methods described above. The c.1062G>C wild type allele was lost in the tumour, strongly suggesting loss of heterozygosity (LOH) (Figure 3).

Two years after the identification of the pulmonary metastases, the patient remains clinically well. His WHO performance status is 1. He has been included in a clinical trial at the Gustave Roussy Cancer Campus, and is now on temsirolimus and cetuximab. Previous lines of treatment with gemcitabine-oxaliplatine and docetaxel have had little effect on the tumour.

**Discussion**

Primary clear cell carcinoma of the thyroid is very rare. In two retrospective studies previously published, only three and four of 2784 and 572 thyroidectomies respectively were primary clear cell carcinomas. Such a diagnosis is made when at least 75% of the tumour cells show marked cytoplasmic clearing. This morphological pattern can occur in nearly all major thyroid tumour types, and is observed with the accumulation of vesicles derived from mitochondria, glycogen, lipid droplets, thyroglobulin or mucin.

To our knowledge, this is the first time that the association between a non-renal clear cell carcinoma and BHD has been demonstrated. FLCN is a tumour suppressor gene, and associated tumours arise when both copies are inactivated most often through “second hit” somatic mutations. In our patient, LOH provides molecular evidence for the inactivation of the second copy of FLCN. Interestingly, the microscopic features of thyroid clear cell carcinoma are similar to those of clear cell RCC, a tumour typically associated with BHD. The TTF-1 positivity and the absence of renal lesions on successive PET/CTs confirmed that our patient’s carcinoma originated in the thyroid, and not in the kidneys. As for the negativity for thyroglobulin, it was not unexpected since this staining is notoriously inconsistent in clear cell tumours of the thyroid.

One should enquire about a personal or family history of BHD manifestations in patients with a diagnosis of thyroid clear cell carcinoma, and refer them for germline FLCN analysis when appropriate. Adult relatives of mutation carriers can then undergo targeted genetic testing. It is paramount to identify patients with BHD, as they are offered regular cancer screening with annual renal imaging (we alternate MRI and ultrasound imaging) and benefit from lifestyle recommendations. We advise patients not to smoke in order to minimize the risk of pneumothorax, and we inform them that activities such as deep sea diving or flying can trigger rupture of pulmonary cysts via changes in the atmospheric pressure, and that shortness of breath or chest pain in this context is likely due to pneumothorax.

Our report is of high scientific interest as, to our knowledge, no such case has ever been reported. In addition, we believe that it

---

**Figure 3. FLCN sequences.** The c.1062G>C wild type allele in exon 9 is lost in the tumour, while the patient is heterozygote for the mutation in the germline. Top sequence, control DNA. Middle sequence, germline DNA (normal tissue). Bottom sequence, tumour DNA.
will increase awareness of BHD in the medical community, as this syndrome is too often overlooked even when obvious clinical manifestations are present.

**Consent**
The patient described in this manuscript has provided informed written consent for his medical history and clinical images to appear in a scientific article.

**Author contributions**
PRB, CM, and EC were involved in the clinical management of the case. PRB also provided genetic counselling and wrote the manuscript (with support from the other authors). SG and TF performed the genetic analyses on the tumour. JL performed germline genetic analyses on the DNA extracted from blood. EL and SF were involved as pathologists. All authors approved the final version of the manuscript.

**Competing interests**
No competing interests were disclosed.

**Grant information**
Financial support to the PREDIR Centre (PRB, SF) and the INSERM U753 Research Unit (SG) is provided continuously by the Ligue Nationale contre le Cancer (Comités de l’Indre et du Cher), the Myrovltytis Trust (BHD Foundation) and the Fondation Gustave Roussy.

**Acknowledgments**
We thank Mrs Frederique Legale who provided valuable secretarial assistance.

**References**

Open Peer Review

Current Peer Review Status: ✔ ✔

Version 1

Reviewer Report 03 September 2014
https://doi.org/10.5256/f1000research.4503.r6020

© 2014 Sappino A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andre-Pascal Sappino
Centre d'oncologie et d'hématologie, Clinique des Grangettes, Chêne-Bougeries, Switzerland

The case report submitted by Benusiglio et al. is well documented and provides convincing evidence that we should consider widening the tumor spectrum generally ascribed to the rare Birt-Hogg-Dubé syndrome. Indeed, the authors report the case of a 72 y-old patient with a suggestive familial and personal history who developed a primary clear-cell carcinoma of the thyroid. Gene-testing for FLCN revelead a germ-line deleterious mutation and LOH for FLCN was demonstrated in the thyroid tumoral tissue. This finding is of interest since most (all ?) cancers described so far in this syndrome arise from the kidneys.

Altogether, the title, the abstract, and the article content, based on adequate methodology, are appropriate. However, we are told that the reported patient developed at the age of 64 an early-stage rectal cancer. It would have been interesting to know more about the morphological aspects of this primary digestive tumor and if the authors could also perform on this primary the search for FLCN LOH. This information may be relevant since the median age of tumor diagnosis in this syndrome is generally considered to occur below 50 y, a point that the authors fail to discuss.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 22 August 2014
https://doi.org/10.5256/f1000research.4503.r5429

© 2014 Philip N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nicole Philip
Département de Génétique Médicale et de Biologie Cellulaire, Assistance Publique - Hopitaux de Marseille, Marseille, France

This short report provides new knowledge on a very rare disorder, the Birt-Hogg-Dube syndrome. The presence of LOH in the tumor is a strong argument to conclude that the tumor is related to the syndrome. This new information can be useful for clinicians to diagnose new patients and offer appropriate surveillance.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.